Walleye Trading’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-100
Closed -$27.5K 4789
2025
Q4
$27.5K Buy
+100
New +$27.4K ﹤0.01% 4069
2025
Q3
Sell
-1,700
Closed -$372K 4881
2025
Q2
$372K Sell
1,700
-1,700
-50% -$363K ﹤0.01% 2861
2025
Q1
$761K Buy
+3,400
New +$937K ﹤0.01% 2238
2024
Q4
Sell
-200
Closed -$60K 4724
2024
Q3
$60K Sell
200
-300
-60% -$91.9K ﹤0.01% 3479
2024
Q2
$165K Sell
500
-10,300
-95% -$3.64M ﹤0.01% 3186
2024
Q1
$4.27M Buy
10,800
+5,500
+104% +$2.03M 0.01% 1239
2023
Q4
$1.87M Buy
5,300
+3,200
+152% +$1.13M ﹤0.01% 1976
2023
Q3
$788K Buy
2,100
+1,600
+320% +$619K ﹤0.01% 2559
2023
Q2
$191K Buy
500
+200
+67% +$71.4K ﹤0.01% 3454
2023
Q1
$104K Sell
300
-600
-67% -$175K ﹤0.01% 3835
2022
Q4
$212K Sell
900
-200
-18% -$47.4K ﹤0.01% 3530
2022
Q3
$271K Buy
+1,100
New +$335K ﹤0.01% 3442
2022
Q2
Sell
-400
Closed -$164K 5748
2022
Q1
$164K Sell
400
-100
-20% -$39.1K ﹤0.01% 3954
2021
Q4
$235K Buy
500
+300
+150% +$129K ﹤0.01% 3732
2021
Q3
$85K Hold
200
﹤0.01% 4450
2021
Q2
$72K Buy
+200
New +$66.1K ﹤0.01% 4505

Other funds holding WST

Walleye Trading's WST Position: Q1 2026 in Review

Walleye Trading sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 663 shares — an estimated $182K sold.

Walleye Trading first reported a position in WST in Q3 2016 and held it in 12 quarters. The position peaked at $1.77M in Q2 2025. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Walleye Trading reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 663 West Pharmaceutical shares in Q1 2026, an estimated $182K.
  • Walleye Trading first reported a position in West Pharmaceutical in Q3 2016 and held it in 12 quarters.
  • Walleye Trading's West Pharmaceutical position peaked at $1.77M in Q2 2025.
  • 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.